Skip to main content

Safety of bevacizumab in patients younger than 4 years of age

Abstract

Purpose

Limited data exist regarding the safety and efficacy of bevacizumab in pediatric patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 years of age treated with bevacizumab.

Methods

The primary objective was to document adverse events with a possible relationship to bevacizumab. Patients (n = 16) were identified through retrospective chart review and harbored a variety of conditions (44 % central nervous system (CNS) tumors, 31 % vascular anomalies, 13 % neuroblastoma, 12 % other).

Results

The median age was 34.3 months (range 4.9–47.3), including five patients <2 years of age. Patients received bevacizumab for a median duration of 6.2 months, alone or with chemotherapy, and a median dose of 9.25 mg/kg (range 7.0–11.8). Partial responses were seen in 19 % of patients, and clinical improvements were seen in 69 %. Adverse events known to be associated with bevacizumab occurred in 37 %. Outcomes observed in this population resemble those reported for bevacizumab in older pediatric patients. The overall pattern and frequency of adverse events observed was similar to those seen in reports of older pediatric patients with a variety of conditions. The highest level of efficacy observed was seen among patients with vascular malformations or with low-grade CNS tumors.

Conclusions

Our results suggest that the use of bevacizumab is safe for the youngest children.

This is a preview of subscription content, access via your institution.

References

  1. Glade Bender J, Yamashiro DJ, Fox E. Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist. 2011;16:1614–25.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Greenberger S, Bischoff J. Infantile hemangioma—mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med. 2011;1:a006460.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Megison ML, Gillroy LA, Beierle EA. Cell survival signaling in neuroblastoma. Anticancer Agents Med Chem. 2013;13:563–75.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Schiavetti A, Ingrosso A, Antenucci A, Federici T, Megaro G, De Luca L, et al. Circulating vascular endothelial growth factor in childhood solid tumors: plasma and serum measurements. Anticancer Res. 2012;32:3565–9.

    CAS  PubMed  Google Scholar 

  5. Hintsala E, Bono P, Andersson S, Kivivuori SM. Quantification of plasma and bone marrow VEGF and angiopoietin-2 levels in pediatric malignancies. J Pediatr Hematol Oncol. 2012;34:503–10.

    CAS  Article  PubMed  Google Scholar 

  6. Berendsen AD, Olsen BR. How vascular endothelial growth factor-A (VEGF) regulates differentiation of mesenchymal stem cells. J Histochem Cytochem. 2014;62:103–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126:1149–59.

    CAS  PubMed  Google Scholar 

  8. Aguilera D, Mazewski C, Fangusaro J, MacDonald TJ, McNall-Knapp RY, Hayes LL, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013;29:589–96.

    Article  PubMed  PubMed Central  Google Scholar 

  9. de Pasquale MD, Castellano A, de Sio L, de Laurentis C, Mastronuzzi A, Serra A, et al. Bevacizumab in pediatric patients: how safe is it? Anticancer Res. 2011;31:3953–7.

    PubMed  Google Scholar 

  10. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2012;116(2):341–5.

    CAS  Article  PubMed  Google Scholar 

  11. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 2013;19:236–246. Erratum in: Clin Cancer Res. 2013;19:1914.

  12. Hsu CH, Lober RM, Li MD, Partap S, Murphy PA, Barnes PD, Fisher PG, Yeom KW. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab. J Neurooncol. 2015;122(3):491–6.

    CAS  Article  PubMed  Google Scholar 

  13. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014;16(2):310–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132(1):111–4.

    Article  PubMed  Google Scholar 

  15. Venkatramani R, Malogolowkin MH, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014;61(4):756–9.

    Article  PubMed  Google Scholar 

  16. Conde N, Cruz O, Albert A, Mora J. Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma. Pediatr Blood Cancer. 2011;57(6):1071–3.

    Article  PubMed  Google Scholar 

  17. Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, et al. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children’s Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015;62(1):45–51.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Support for third-party medical writing assistance was funded by Genentech, Inc.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Mora.

Ethics declarations

Conflict of interest

All authors declare no conflicts of interest to disclose.

Financial disclosure

The authors have no financial relationships relevant to this article to disclose.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Millan, N.C., Poveda, M.J., Cruz, O. et al. Safety of bevacizumab in patients younger than 4 years of age. Clin Transl Oncol 18, 464–468 (2016). https://doi.org/10.1007/s12094-015-1389-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1389-5

Keywords

  • Bevacizumab
  • Infant and toddlers
  • Antiangiogenesis
  • Infant tumors